|
|
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
S. Delaloge
,
David Perol
,
C. Courtinard
,
E. Brain
,
B. Asselain
et al.
Journal articles
hal-02262350v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
J.E. Martin
,
S. Khalife-Hachem
,
T. Grinda
,
M. Kfoury
,
S. Garciaz
et al.
Journal articles
hal-03623367v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial
J. Lemonnier
,
L. Roca
,
S. Mijonnet
,
P. Gesta
,
J. Chiesa
et al.
Journal articles
istex
hal-02282759v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
T. Grinda
,
A. Antoine
,
W. Jacot
,
C. Blaye
,
P. H. Cottu
et al.
Journal articles
hal-03273275v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
J.E. Martin
,
S. Khalife-Hachem
,
T. Grinda
,
M. Kfoury
,
S. Garciaz
et al.
Journal articles
hal-03376715v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|